Scarica l'app Stockscreener
1.25
0.81%
0.01
Dopo l'orario di chiusura:
1.20
-0.05
-4.00%
Precedente Chiudi:
$1.24
Aprire:
$1.21
Volume 24 ore:
105.54K
Relative Volume:
0.23
Capitalizzazione di mercato:
$62.35M
Reddito:
$96.63M
Utile/perdita netta:
$-63.32M
Rapporto P/E:
-0.8562
EPS:
-1.46
Flusso di cassa netto:
$-54.55M
1 W Prestazione:
-0.79%
1M Prestazione:
-1.57%
6M Prestazione:
-43.18%
1 anno Prestazione:
-40.76%
Intervallo 1D:
$1.21
$1.255
Intervallo di 1 settimana:
$1.205
$1.32
Portata 52W:
$0.931
$3.42
Akoya Biosciences Inc Stock (AKYA) Company Profile
Nome
Akoya Biosciences Inc
Settore
Industria
Telefono
855.896.8401
Indirizzo
100 CAMPUS DRIVE, MARLBOROUGH
Confronta AKYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.25 | 62.84M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
552.34 | 193.38B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
172.59 | 49.12B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
85.94 | 42.79B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
244.79 | 35.61B | 5.02B | 1.31B | 1.56B | 8.91 |
|
BAX
Baxter International Inc
|
30.50 | 15.46B | 11.89B | -560.00M | 191.00M | -1.10 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-15 | Downgrade | Craig Hallum | Buy → Hold |
| 2024-08-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Iniziato | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-02-02 | Iniziato | UBS | Buy |
| 2022-11-03 | Iniziato | CapitalOne | Overweight |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-06-22 | Iniziato | BTIG Research | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-05-11 | Iniziato | Canaccord Genuity | Buy |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Morgan Stanley | Overweight |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Akoya Biosciences Inc Borsa (AKYA) Ultime notizie
Spatial proteomics Market Worth Observing Growth: Bruker, Akoya Biosciences, PerkinElmer - newstrail.com
Spatiotemporal Omics Market Research Report 2025-2035, Competitive Analysis of Prominent Players10X Genomics, Akoya Biosciences, Bruker, Curio Bioscience, IonPath, MGI, and RareCyteResearchAndMarkets.com - FinancialContent
Akoya Biosciences, Inc. (NASDAQ:AKYA) Receives Average Recommendation of “Hold” from Brokerages - Defense World
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs - Benzinga
Akoya Biosciences (AKYA) Soars on New Acquisition Proposal - GuruFocus
An undisclosed buyer agreed to acquire Akoya Biosciences, Inc.. - marketscreener.com
Akoya Biosciences Receives Unsolicited Buyout Offer From Third Party - marketscreener.com
Akoya stock surges as new buyout bid risks Quanterix deal (AKYA) - Seeking Alpha
Akoya Biosciences reviews unsolicited acquisition proposal By Investing.com - Investing.com Nigeria
Akoya Biosciences IncOn May 20, Receives Unsolicited Acquisition Proposal At $1.40 Per Share From A Third Party- SEC Filing - marketscreener.com
Akoya Biosciences reviews unsolicited acquisition proposal - Investing.com
Akoya Biosciences (NASDAQ:AKYA) Given New $1.08 Price Target at Canaccord Genuity Group - Defense World
Akoya Biosciences Reports Q1 2025 Financial Results - TipRanks
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKY - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Sto - GuruFocus
Akoya Biosciences (AKYA): Analyst Lowers Price Target | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Target Price Reduced by Canaccord | AKYA Stock News - GuruFocus
Akoya Biosciences (AKYA) Faces Uncertainty Amid Merger and Marke - GuruFocus
Akoya Biosciences, Inc. SEC 10-Q Report - TradingView
Akoya: Q1 Earnings Snapshot - The Washington Post
Akoya Biosciences earnings missed by $0.11, revenue fell short of estimates - Investing.com Canada
Akoya Biosciences (AKYA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Akoya Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Akoya Biosciences Inc Reports Q1 2025 Earnings: EPS of -$0.18 Be - GuruFocus
Akoya Biosciences Reports First Quarter 2025 Financial Results - The Manila Times
Akoya Biosciences (AKYA) Projected to Post Quarterly Earnings on Monday - Defense World
AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc.AKYA - Business Wire
Akoya Biosciences, Inc. (NASDAQ:AKYA) Shares Acquired by JPMorgan Chase & Co. - Defense World
Quanterix and Akoya Biosciences Announce Amended Merger Agreement - ADVFN
Akoya Biosciences (AKYA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Average Recommendation of “Hold” by Analysts - Defense World
Canaccord Genuity Group Has Lowered Expectations for Akoya Biosciences (NASDAQ:AKYA) Stock Price - Defense World
AKYA Merger Faces Backlash Amid Shareholder Discontent | AKYA St - GuruFocus
Quanterix Acquisition of Akoya Biosciences (AKYA) Faces Challenges | AKYA Stock News - GuruFocus
Kent Lake Issues Statement on Quanterix?s Amendment to Merger with Akoya Biosciences - marketscreener.com
Quanterix, Akoya Biosciences Amend Merger Deal - marketscreener.com
Akoya stock falls on amended Quanterix merger deal (AKYA) - Seeking Alpha
Quanterix Revises Merger Terms with Akoya Biosciences - TipRanks
Merger Amendment: Changes to Quanterix and Akoya Biosciences (AK - GuruFocus
Quanterix And Akoya Biosciences Announce Amended Merger Agreement - marketscreener.com
Canaccord Adjusts Price Target for Akoya Biosciences (AKYA) | AK - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Pacific Premier Bancorp, Inc. (NasdaqPPBI), Southern States Bancshares, Inc. (NasdaqSSBK), Akoya Biosciences, Inc. (NasdaqAKYA) - TradingView
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Res - GuruFocus
Akoya Biosciences (AKYA) Unveils New Assay for Breast Cancer Research | AKYA Stock News - GuruFocus
Akoya Biosciences introduces new assay for breast cancer ADC development - Investing.com Australia
Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - The Manila Times
Akoya Biosciences Expands Biopharma Service Portfolio with - GlobeNewswire
Akoya Biosciences and Enable Medicine Launch the Largest - GlobeNewswire
Revolutionary Cancer Research: 100M+ Cells Atlas Unlocks New Era in Biomarker Discovery - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Akoya Biosciences Inc Azioni (AKYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.66%
1.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):